New Approaches to the Management of Metastatic Bladder Cancer

December 3, 2013
Arjun Balar, MD

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses new approaches to the management of metastatic bladder cancer.

Clinical Pearls

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses new approaches to the management of metastatic bladder cancer.

  • A phase III trial analyzing bevacizumab in combination with chemotherapy in metastatic bladder cancer is currently accruing
  • OGX-427 is an antisense oligonucleotide against Hsp27, which is implicated in chemotherapy resistance
  • It is hypothesized that OGX-427 added to chemotherapy could improve the sensitivity of a tumor to chemotherapy